Foresite Capital Fund IV, L.P. - 04 Feb 2026 SCHEDULE 13G Report for Eikon Therapeutics, Inc. Common Stock, par value $0.0001

Filing Manager
Foresite Capital Fund IV, L.P.
Reporting Manager
James B. Tananbaum
Security
Eikon Therapeutics, Inc. Common Stock, par value $0.0001
Shares outstanding
53,876,870 shares
Disclosed Ownership
4,148,519 shares
Ownership
7.7%
Form type
SCHEDULE 13G
Filing time
11 Feb 2026, 16:08:44 UTC
Date of event
04 Feb 2026
SEC
View on sec.gov

Reporting Managers (9)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Foresite Capital Fund IV, L.P. 3.6% 1,960,774 1,960,774 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management IV, LLC 3.6% 1,960,774 1,960,774 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Fund V, L.P. 2.5% 1,353,168 1,353,168 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management V, LLC 2.5% 1,353,168 1,353,168 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Opportunity Fund V, L.P. 0.8% 425,852 425,852 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Opportunity Management V, LLC 0.8% 425,852 425,852 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital VI-A, LLC 0.8% 408,725 408,725 0 /s/ James Tananbaum James Tananbaum, Managing Member of the Managing Member
Foresite Capital VI-A Management, LLC 0.8% 408,725 408,725 0 /s/ James Tananbaum James Tananbaum, Managing Member
James B. Tananbaum 7.7% 4,148,519 4,148,519 0 /s/ James Tananbaum James Tananbaum